Posted by Michael Wonder on 20 Jun 2022
PHARMAC's latest breast cancer drug funding 'way short' - advocate
16 June 2022 - On Wednesday PHARMAC announced $190 million to fund cancer treatments and other medicines.
Included in the funding is trastuzumab emtansine to treat breast cancer in the early stages.
But Breast Cancer Aotearoa Coalition chair Libby Burgess says the funding allocation means breast cancer patients can only have one treatment of the drug, even if the cancer advances.
Editor'e note - trastuzumab emtansine is NOT Herceptin
